Do GLP-1 medications increase the risk of diabetic retinopathy?

GLP-1 medications and rapid glucose improvement can potentially worsen diabetic retinopathy, particularly in the short term. The SUSTAIN-6 trial initially raised concerns about increased retinopathy events with semaglutide, though longer-term data is more reassuring. The mechanism appears related to rapid glucose lowering rather than the medication itself - called 'early worsening' of retinopathy. When blood sugar drops quickly, it can temporarily stress retinal blood vessels. However, longer-term studies show neutral or beneficial effects on retinopathy progression. Patients with existing diabetic retinopathy should have eye exams before starting GLP-1s and regularly during treatment. Those with proliferative retinopathy or recent laser treatment may need to delay GLP-1 initiation until their eye condition is stable. The cardiovascular and kidney benefits of GLP-1s generally outweigh retinopathy concerns for most diabetic patients. Work closely with both your endocrinologist and ophthalmologist if you have diabetic eye disease.